Implications of cytochrome P450 interactions when prescribing medication for hypertension

David A. Flockhart, Jose E. Tanus-Santos

Research output: Contribution to journalReview articlepeer-review

94 Scopus citations


Many of the estimated 50 million Americans with high blood pressure receive medications for hypertension and for other conditions, placing them at risk for adverse drug interactions. The risk for hypertension and for adverse drug reactions is highest in the elderly, who have the greatest need for pharmacologic therapy. The most important class of drug interactions involves the cytochrome P450 microsomal enzyme system, which handles a variety of xenobiotic substances. A potential for interactions with these enzymes exists with calcium channel blockers, β-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers but not with diuretic antihypertensives, which are renally eliminated and more vulnerable to drug interactions that occur in the kidney. This article reviews the cytochrome P450 enzyme system, identifies drugs and foods that have been implicated in metabolic interactions with antihypertensive agents, and suggests measures for reducing the risk of adverse events when drugs are coadministered.

Original languageEnglish (US)
Pages (from-to)405-412
Number of pages8
JournalArchives of Internal Medicine
Issue number4
StatePublished - Feb 25 2002

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Implications of cytochrome P450 interactions when prescribing medication for hypertension'. Together they form a unique fingerprint.

Cite this